TISSUE-TYPE PLASMINOGEN-ACTIVATOR, A NEW PROGNOSTIC MARKER IN BREAST-CANCER
- 1 March 1988
- journal article
- research article
- Vol. 48 (5) , 1348-1349
Abstract
Plasminogen activator is a protease existing in two forms known as tissue-type and urokinase-type plasminogen activator. In this investigation, patients with breast cancers containing high levels of the tissue-type enzyme had a significantly longer disease-free interval and survival compared with patients with low levels of the enzyme. For the disease-free interval, the effect of tissue-type plasminogen activator was independent of tumor stage, grade, axillary node involvement, and estradiol receptor status. It is concluded that tissue-type plasminogen activator is a new prognostic marker in breast cancer.This publication has 7 references indexed in Scilit:
- PREDICTIVE VALUE OF LECTIN BINDING ON BREAST-CANCER RECURRENCE AND SURVIVALThe Lancet, 1987
- Plasminogen activators in human colorectal neoplasia.BMJ, 1986
- Tissue-Type Plasminogen Activator in Breast Cancer: Relationship With Estradiol and Progesterone ReceptorsJNCI Journal of the National Cancer Institute, 1986
- MULTIPLE FORMS OF PLASMINOGEN-ACTIVATOR IN HUMAN-BREAST TUMORS1985
- Progesterone Receptors as a Prognostic Factor in Stage II Breast CancerNew England Journal of Medicine, 1983
- Antibodies to plasminogen activator inhibit human tumor metastasisCell, 1983
- Cea-like material in cytosols from human breast carcinomas: Correlation with biochemical and pathologic parametersCancer, 1983